HOLD

• RSI at 79.8 on August 19, above 70 for two weeks; MACD histogram flattening at +2.05 after declining from earlier peak
• Price is 3% above 10 EMA after 17-session, 18.6% run — late innings of a thrust, not a confirmed regime
• Forward P/E of 18.1x looks attractive but trailing P/E is 27.5 with PEG of 2.31 — premium multiples on premium prices
• Stock up 51.8% over past year, 18.5% in past 30 days, 60% off 52-week low
• Current price $442.24 vs Argus target of $460 = only ~4% upside; potential 14% drawdown to 50 SMA at $380
• Consensus EPS $24.40, now priced in — 27.5 trailing P/E reflects known information
• Trim recommended at $453.58 (Bollinger upper band) with RSI above 80; aggressive analyst's plan to wait for RSI 85 with confirmed divergence means giving back 5-15% before acting
• Adding fresh capital at $442 violates first-principles: stock is 16% above 50-day MA and 26% above 200-day MA
• $380 pullback to 50 SMA framed as a 'gift' — logically inconsistent to believe this and refuse to wait at $442
• Healthcare sector at record highs signals the easy rotation trade is mature; don't add at sector highs
• Balance sheet concerns: $43 billion net debt, negative tangible book value, $39 billion goodwill/intangibles
• Horizon deal amortization ~$1.1 billion per quarter; MariTide faces direct competition from Zepbound and Wegovy in $100B+ TAM
• Debt-to-equity ratio of 4.9x leaves limited margin for error on pipeline stumbles
• Recommend trim 20-30% at $453 with trailing stop on remainder at $429 or $440 if breakout confirmed
• Add framework: pullback to $429 (~$12 discount), more aggressive tranche near $412 if RSI resets and MACD turns up
• Capital preservation compounds across cycles; aggressive plan optimizes for this trade, conservative plan optimizes for next ten trades

→ vs aggressive: The RSI overbought argument is not merely a regime indicator — stacking overbought RSI (79.8, above 70 for two weeks) with decelerating MACD histogram (+2.05, flattening) and price extended 3% above 10 EMA after 18.6% run signals late innings, not confirmation of trend strength

→ vs aggressive: Valuation is not a gift at current levels — forward P/E of 18.1x looks attractive but 27.5 trailing P/E and 2.31 PEG reflect priced-in expectations; 4% upside to Argus target ($460) versus 14% potential drawdown to $380 creates negative asymmetry

→ vs aggressive: Waiting until RSI hits 85 with confirmed bearish divergence before trimming is reactive, not proactive — means giving back 5-15% of recent gains before acting, contradicting the goal of protecting accumulated profits

→ vs aggressive: Adding at $442 when stock is 60% off 52-week low, 16% above 50-day MA, and 26% above 200-day MA violates first-principles risk management regardless of fundamental conviction

→ vs aggressive: Cannot simultaneously claim $380 pullback is a 'gift' while refusing to wait for it at $442 — these positions are logically inconsistent; either you want the discount or you don't

→ vs aggressive: Higher-for-longer macro is selectively optimistic — it also compresses multiples on any disappointment, punishes earnings misses, caps defensive name run, and SCHD inflows are thematic not stock-specific catalyst

→ vs aggressive: Biosimilar Humira impact is not fully rearview — $43B net debt, negative tangible book value, $39B goodwill/intangibles, and $1.1B/quarter Horizon amortization leave the company vulnerable to pipeline stumbles (MariTide faces Zepbound/Wegovy competition in crowded $100B+ TAM)

HOLD with refined execution framework: hold core position with 380 daily close stop, deploy modest 15-20% starter tranche at current levels with 410 tight stop, preserve pullback add discipline at 429 (10 EMA) and 412 (Bollinger middle) zones requiring RSI reset and MACD histogram reacceleration as confirmation, and replace price-only trim with conditional trim on combined topping signals (RSI above 80, MACD histogram rolling over, and extension into resistance at 453).

• MACD histogram at plus 2.05 is a yellow light, not green, after running at higher levels — momentum is decelerating but not reversing
• Forward P/E of 18.1 is fairly priced for execution but richly priced for disappointment; trailing P/E of 27.5 reflects premium for unproven growth
• Stock up 18.5 percent in a month after 18.6 percent run in 17 sessions; ATR of 10.50 suggests meaningful daily volatility
• Conditional trim replaces automatic 20-30% trim at 453 — trim only on combination of extension into resistance, RSI pushing toward 80, and MACD histogram rolling over
• Healthcare sector at record highs is a constraint, not a tailwind — the sector lift is mature, not nascent
• Intangible amortization of approximately 1.1 billion per quarter and net debt of 43 billion against equity under 12 billion create asymmetric downside risk
• MariTide pipeline faces direct competition from Zepbound and Wegovy in crowded TAM
• Beta of 0.41 and yield of 2.27 percent favor Amgen in higher-for-longer environment but cap multiple expansion
• Next two quarters of earnings delivery will drive the stock more than multiple expansion

→ vs aggressive: Ignoring MACD histogram deceleration while claiming momentum edge — can't claim trend momentum is your edge while dismissing the part of momentum that's already decelerating

→ vs aggressive: Forward P/E of 18.1 is not automatically cheap when trailing P/E is 27.5 — market is paying premium for growth that hasn't materialized yet, not a guaranteed bargain

→ vs aggressive: Trim at RSI 85 with confirmed bearish divergence is too late — by that point momentum has already rolled and you're trimming at diminished strength

→ vs aggressive: Too dismissive of patent risks, balance sheet (net debt 43 billion, equity under 12 billion), and pipeline competition from Zepbound/Wegovy

→ vs conservative: RSI 74 is not a sell signal in isolation — in this trend it means upper third of trading range demanding entry discipline, not exit discipline

→ vs conservative: Zero deployment until 429 is overconfident in directional call and leaves too much on the table if the stock accelerates on a sector tape

→ vs conservative: Automatic 20-30% trim at 453 on first tag of upper band is too early — trim on breakout tag is fading a winner, not managing risk proactively

→ vs conservative: Automatic trim at 453 ignores whether MACD is still positive and histogram is expanding — that's trend continuation, not a trim signal